Biden-Harris Administration Moves Forward with Medicare Drug Price Negotiations to Lower Prescription Drug Costs for People with Medicare
Portfolio Pulse from Charles Gross
The Biden-Harris administration is advancing with plans to negotiate Medicare drug prices in an effort to reduce prescription drug costs for Medicare beneficiaries.
October 03, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The move to negotiate Medicare drug prices could potentially impact the revenues of pharmaceutical companies included in the VanEck Vectors Pharmaceutical ETF (PPH).
The negotiation of Medicare drug prices could lead to lower prices, which could in turn reduce the revenues of pharmaceutical companies. As PPH is an ETF that includes these companies, it could be negatively impacted.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
The S&P 500 ETF (SPY) could be indirectly affected by the Biden-Harris administration's move to negotiate Medicare drug prices, as it includes healthcare companies.
The S&P 500 ETF (SPY) includes healthcare companies that could be affected by the negotiation of Medicare drug prices. This could potentially lead to a decrease in the ETF's value.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 60